Immunohistochemical Expression of BRCA1 and Lethal Prostate Cancer

被引：26

作者：

Fiorentino, Michelangelo ^{[1
,9
]}

Judson, Gregory ^{[2
,3
]}

Penney, Kathryn ^{[2
,3
]}

Flavin, Richard

Stark, Jennifer ^{[2
,3
]}

Fiore, Christopher

Fall, Katja ^{[2
,3
,10
]}

Martin, Neil ^{[3
,6
]}

Ma, Jing ^{[2
]}

Sinnott, Jennifer ^{[2
,5
]}

Giovannucci, Edward ^{[2
,3
,4
]}

Stampfer, Meir ^{[2
,3
,4
]}

Sesso, Howard D. ^{[3
,7
]}

Kantoff, Philip W. ^{[8
,11
]}

Finn, Stephen

Loda, Massimo ^{[11
]}

Mucci, Lorelei ^{[2
,3
]}

机构：

[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Mol Oncol Pathol,Dept Pathol, Boston, MA 02115 USA

[2] Harvard Univ, Sch Med, Channing Lab, Brigham & Womens Hosp,Dept Med, Boston, MA 02115 USA

[3] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA

[4] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA

[5] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA

[6] Brigham & Womens Hosp, Boston, MA 02115 USA

[7] Harvard Univ, Sch Med, Div Prevent Med, Brigham & Womens Hosp,Dept Med, Boston, MA 02115 USA

[8] Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA

[9] St Orsola Marcello Malpighi Hosp, Pathol Unit, Addarii Inst, Bologna, Italy

[10] Univ Uppsala Hosp, Uppsala, Sweden

[11] Broad Inst, Cambridge, MA USA

来源：

CANCER RESEARCH | 2010年 / 70卷 / 08期

关键词：

MAMMARY EPITHELIAL-CELLS; MUTATION CARRIERS; GLEASON SCORE; CYCLE CONTROL; DNA-DAMAGE; GENE; TRANSCRIPTION; PHYSICIANS; TRIAL; MEN;

D O I：

10.1158/0008-5472.CAN-09-4100

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BRCA1 functions as a tumor suppressor; recent work suggests that BRCA1 may also induce cell cycle arrest to allow for DNA repair. We hypothesized that BRCA1 expression in prostate tumor tissue may be associated with prostate cancer progression through regulation of the cell cycle. We used immunohistochemistry to evaluate BRCA1 protein expression in archival tumor samples from 393 prostate cancer cases in the Physicians' Health Study. The men were followed prospectively from diagnosis to development of metastases and mortality. Fifteen percent of tumors stained positive for BRCA1. BRCA1-positive tumors had substantially increased tumor proliferation index compared with negative tumors (47.0 Ki67-positive nuclei versus 10.3, P = 0.0016) and were more likely to develop lethal cancer compared with BRCA1-negative tumors (hazard ratio, 4.6; 95% confidence interval, 2.4-8.7). These findings strengthen the hypothesis that BRCA1 plays a role in cell cycle control and show that BRCA1 is a marker of clinical prostate cancer prognosis. Cancer Res; 70(8); 3136-9. (C) 2010 AACR.

引用

页码：3136 / 3139

页数：4

共 21 条

[1] Associations of High-Grade Prostate Cancer with BRCA1 and BRCA2 Founder Mutations [J].